Immunotherapy for Cancer in India 2026: Types, Approved Drugs, Costs & Eligibility for International Patients
Immunotherapy for Cancer Treatment in India
Cancer treatment has changed fundamentally over the past decade. Immunotherapy — which trains the body's own immune system to recognise and destroy cancer cells — has moved from experimental trials to standard care for many tumour types. For international patients, India now offers the full range of immunotherapy options at costs 40 to 60 percent lower than the USA or Europe.
TL;DR: India offers checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab), monoclonal antibodies, and CAR-T cell therapy at 40–60% lower cost than the West. Biosimilar availability reduces costs further. Eligibility requires biomarker testing, which Indian hospitals can perform on samples sent before travel. Treatment typically costs USD 1,200–2,500 per cycle.
What Is Immunotherapy?
Unlike chemotherapy, which attacks all rapidly dividing cells, immunotherapy works by enhancing or restoring the immune system's natural ability to detect and fight cancer. There are several categories, each with distinct mechanisms.
Checkpoint Inhibitors
Cancer cells often produce proteins that act as "brakes" on immune cells, preventing them from attacking the tumour. Checkpoint inhibitors release those brakes.
The three main targets are:
- PD-1 inhibitors — pembrolizumab (Keytruda) and nivolumab (Opdivo) block the PD-1 receptor on T-cells, restoring their ability to recognise tumour cells
- PD-L1 inhibitors — atezolizumab (Tecentriq) and durvalumab (Imfinzi) block the corresponding ligand on the tumour cell surface
- CTLA-4 inhibitors — ipilimumab (Yervoy) blocks a different checkpoint, often used in combination with PD-1 inhibitors for melanoma and renal cell carcinoma
All of these drugs are approved and available at major Indian cancer centres.
CAR-T Cell Therapy
Chimeric antigen receptor T-cell therapy takes a patient's own T-cells, genetically modifies them in a laboratory to recognise a specific cancer antigen, and infuses the modified cells back into the patient. In India, CAR-T therapy is now available at select centres including Tata Memorial Hospital in Mumbai and certain Apollo and Medanta facilities. India-developed CAR-T products have reduced the cost to approximately USD 30,000–60,000 compared to USD 300,000–500,000 in the USA.
Monoclonal Antibodies
These laboratory-made proteins target specific molecules on cancer cells. Examples include trastuzumab for HER2-positive breast cancer, rituximab for certain lymphomas, and bevacizumab for colorectal and lung cancers. India has a robust biosimilar industry, and biosimilar versions of many monoclonal antibodies are widely available at significantly reduced prices.
Approved Immunotherapy Drugs in India
India's Central Drugs Standard Control Organisation (CDSCO) has approved the major immunotherapy agents used worldwide. Key drugs available at Indian oncology centres include:
| Drug | Brand Name | Primary Indications |
|---|---|---|
| Pembrolizumab | Keytruda | Lung, melanoma, head & neck, bladder, gastric |
| Nivolumab | Opdivo | Lung, renal, melanoma, Hodgkin lymphoma, liver |
| Atezolizumab | Tecentriq | Lung, bladder, breast (triple-negative) |
| Durvalumab | Imfinzi | Lung (stage III), bladder |
| Ipilimumab | Yervoy | Melanoma, renal (combination therapy) |
The availability of these drugs means that international patients receive the same treatment protocols recommended by NCCN and ESMO guidelines. Indian oncologists trained at international fellowships follow evidence-based protocols identical to those at Memorial Sloan Kettering or MD Anderson.
Cancers Treated with Immunotherapy
Immunotherapy has demonstrated meaningful survival benefits across multiple tumour types:
- Non-small cell lung cancer — pembrolizumab is now first-line therapy for tumours with high PD-L1 expression, often combined with chemotherapy
- Melanoma — combination nivolumab plus ipilimumab produces five-year survival rates exceeding 50 percent in advanced melanoma
- Bladder cancer — atezolizumab and pembrolizumab are options for patients who cannot tolerate cisplatin-based chemotherapy
- Head and neck squamous cell carcinoma — pembrolizumab has become first-line treatment for recurrent or metastatic disease
- Hodgkin lymphoma — nivolumab and pembrolizumab achieve high response rates in relapsed disease
- Renal cell carcinoma — combination immunotherapy has largely replaced targeted therapy as the first-line standard
- Hepatocellular carcinoma — atezolizumab plus bevacizumab is now the preferred first-line regimen
Not every patient with these cancers will benefit from immunotherapy. Eligibility depends on specific biomarkers, which brings us to the testing process.
Determining Eligibility
Before starting immunotherapy, the oncology team needs to establish whether your tumour is likely to respond. Key tests include:
- PD-L1 immunohistochemistry — measures the percentage of tumour cells expressing PD-L1. Higher expression generally predicts better response to checkpoint inhibitors.
- Microsatellite instability (MSI) testing — tumours that are MSI-high respond well to pembrolizumab regardless of the cancer type.
- Tumour mutational burden (TMB) — a high number of mutations correlates with better immunotherapy response.
- Next-generation sequencing (NGS) — comprehensive genomic profiling that identifies actionable mutations and predicts immunotherapy benefit.
Indian hospitals can perform these tests on biopsy tissue shipped before travel, or on fresh biopsies taken on arrival. This allows the oncology team to confirm your treatment plan before you commit to the trip. Submit your reports for a free review to begin this process.
Cost Comparison
The cost advantage of receiving immunotherapy in India is substantial, driven partly by lower healthcare infrastructure costs and partly by India's biosimilar pharmaceutical industry.
| Treatment | India (USD) | USA (USD) |
|---|---|---|
| Pembrolizumab per cycle | 1,500–2,500 | 10,000–15,000 |
| Nivolumab per cycle | 1,200–2,000 | 8,000–12,000 |
| CAR-T cell therapy (total) | 30,000–60,000 | 300,000–500,000 |
| Biomarker testing (NGS panel) | 800–1,500 | 3,000–6,000 |
Biosimilar versions of trastuzumab and rituximab are available in India at 30–40 percent less than originator brands, further reducing the overall cost of treatment. These biosimilars are approved by Indian regulators and meet the same efficacy and safety standards.
Side Effects and Management
Immunotherapy side effects differ from chemotherapy. Because these drugs activate the immune system broadly, they can cause inflammation in healthy organs — known as immune-related adverse events (irAEs):
- Skin — rash, itching, vitiligo (common, usually mild)
- Gastrointestinal — diarrhea, colitis (requires prompt treatment with steroids if severe)
- Liver — hepatitis detected on blood tests, usually asymptomatic
- Lungs — pneumonitis causing cough and breathlessness (occurs in approximately 3–5 percent of patients)
- Endocrine — thyroid dysfunction, adrenal insufficiency, type 1 diabetes (rare)
Indian oncology centres follow international guidelines for irAE management. Most side effects are reversible with corticosteroids or temporary treatment pauses. Severe irAEs requiring hospitalisation occur in roughly 10–15 percent of patients. Hospitals like Tata Memorial, Apollo, and Fortis have dedicated immuno-oncology teams trained to manage these events.
Planning Immunotherapy Treatment in India
Immunotherapy often involves multiple cycles over several months. International patients have two practical approaches:
- Complete treatment in India — stay for the full course (typically 4–6 months for initial cycles), suitable for patients who can arrange extended accommodation
- Start in India, continue at home — receive the first two to three cycles in India, establish tolerability, and continue with a local oncologist using the same protocol
Arodya helps coordinate both approaches, including treatment planning, hospital selection, and accommodation. The oncology team provides a detailed treatment protocol that your home oncologist can follow.
If you or a family member has been diagnosed with cancer and wants to explore immunotherapy options in India, the first step is to request a free case evaluation. Include your pathology report, imaging, and any biomarker test results you already have. The oncology team will review your case and advise on treatment options, expected costs, and timeline.
